Aims: Dehydroepiandrosterone (DHEA) is an adrenal steroid hormone that is a precursor of sexual hormones. It is reduced during aging and is strongly associated with insulin resistance and obesity. There is evidence for beneficial effects of this steroid, in both human and animal models, during perimenopause. However, the impact of DHEA treatment during late postmenopause on glucose metabolism is not clearly documented. We tested the hypothesis that DHEA supplementation could improve insulin sensitivity in an ovariectomized obese rat model (OVX) that was fed a high-fat diet for 11 weeks. Main methods: Female Wistar rats at 8 weeks of age were OVX or SHAM-operated. Eight weeks after the surgery, the animals were randomly treated with vehicle or DHEA for 3 weeks. Food intake, metabolic parameters and insulin sensitivity were evaluated. Key findings: Following the ovariectomy, increased body weight gain, adiposity index, and feeding efficiency were observed, despite there being no change in food and energy intake. The OVX rats also displayed glucose intolerance, insulin resistance, decreased insulin-induced IRS1/2 tyrosine phosphorylation in the skeletal muscle, and reduced serum VLDL-c and TAG levels. OVX rats treated with 10 mg/kg DHEA (OVX + DHEA) exhibited estradiol (E 2 ) serum levels similar to SHAM animals, with no change in uterus mass. DHEA treatment also resulted in an increase in energy intake. Significance: Despite the positive effects of DHEA supplementation observed in menopausal women and ovariectomized rats, a potential negative effect on glucose metabolism and insulin action in the late postmenopausal condition in diet-induced obese OVX rats are reported.
Introduction
Estrogens have a role in energy expenditure, body fat regulation and metabolism, and the lack of these steroids play a role in the etiology of obesity and its metabolic complications [1] [2] [3] . Surgically induced or natural menopause has been associated with higher adiposity, insulin resistance, increased mortality associated with cardiovascular disease, type 2 diabetes mellitus (T2DM), and nonalcoholic fatty liver disease (NAFLD) [4, 5] . Estrogen replacement therapy (HT), despite having some positive effects on metabolism, has been associated with an increased risk of venothrombotic episodes, stroke, and cholecystitis [6] . Thus, investigating new therapeutic strategies for postmenopausal women, rather than classic HT, is of great clinical importance.
Dehydroepiandrosterone (DHEA) and its sulphate form (DHEA-S) represent one of the most abundant circulating androgen and estrogen precursors, mainly secreted by the adrenal glands, ovaries, liver and central nervous system [7] [8] [9] . Previous reports have shown that DHEA and DHEA-S are markedly decreased in human circulation during aging and have also been associated with several age-related metabolic diseases [7, 10, 11] . Interestingly, a specific receptor for DHEA still has not been identified. This steroid has anti-inflammatory effects, reduces the risk of cardiovascular diseases as well as fat accumulation, protects against insulin resistance in both humans [12, 13] and rodents [11, [14] [15] [16] , and inhibits breast cancer cell line proliferation and migration [17] .
We previously reported that administration of DHEA increases insulin sensitivity by activating the PI3K/Akt signaling pathway in the skeletal muscle and liver [18] , improves insulin secretion in pancreatic islets of aged male rats [19] and stimulates insulin production and reduces INS-1E cell apoptosis [20] . Our group also observed how DHEA (13) Data represented as mean ± SD (n). Two-way ANOVA, Tukey's test. Distinct letters indicate statistical significance for P < 0.05. (8) Results are presented as mean ± SD (n). Two-Way ANOVA Tukey's test were used for statistical analysis. Distinct letters indicate statistical significance for P < 0.05. DHEA, dehydroepiandrosterone; E 2 , estradiol; TC, total cholesterol; TAG, triacylglycerol; ALT, aspartate aminotransferase; AST, alanine aminotransferase. treatment improves endothelial function [21] and insulin secretion in ovariectomized (OVX) rats [22] . DHEA is freely commercialized through the internet as a dietary supplement. However, it is not clear if chronic DHEA intake has beneficial effects on insulin sensitivity in late postmenopausal women. Given the widespread use of DHEA for a variety of physiological conditions, such as postmenopause, we hypothetized that supplementing female rats with DHEA 2 months after an ovariectomy, which is an experimental model of late menopause, would improve the expected insulin intolerance in a fashion similar to that reported for male rats [18, 19, 23] and also in OVX rats fed a high-fat diet that induced obesity during the early postmenopausal period [22] . Herein, however, a three week DHEA treatment increased food intake and impaired whole-body insulin sensitivity, without having an effect on body mass or glucose tolerance.
Materials and methods

Experimental design and animal treatment
All experimental procedures were performed in strict accordance with the guidelines of the Brazilian College for Animal Experimentation (COBEA) and approved by the Ethics Committee on Animal Research at the Institute of Biomedical Sciences, University of São Paulo. Female Wistar rats, weighing 195 ± 15 g, were obtained from the breeding colony at the Institute of Biomedical Sciences. At 8 weeks of age, the animals were anesthetized using a ketamine-xylazine-acepromazine mixture (100, 20 and 1 mg·kg , s.c.; Sigma-Aldrich, St. Louis, MO, USA) once a week for 3 weeks, in accordance with our previous studies [21, 22] . During the study, the animals were housed in a temperature controlled room (22 ± 2°C) under a 12 h light/dark cycle and 60% humidity, with free access to water and food. After ovariectomy, a high-fat diet (HFD) with 22.36 kJ·g −1 (34% fat, 36% carbohydrate, 20% protein and 10% fibers and minerals; Prag Soluções Biociências, Jaú, SP, Brazil), containing 88% from saturated fat (lard) and 12% from unsaturated fat (soybean oil) was administered. Previous reports have shown that ovariectomy had no impact on wholebody insulin sensitivity in regular chow-fed rats, whereas OVX rats fed a HFD had insulin resistance [22] . Thus, only rats fed a HFD were evaluated in this work. At the end of the study protocol, food was removed for the final 6 h (from 08:00 am to 02:00 pm), the rats were anesthetized with thiopental (50 mg·kg −1 body weight) and euthanized by decapitation.
Zoometric parameters and food intake
Body mass was determined weekly. In the last week of the experiment, the animals were housed separately and daily food intake was assessed twice by calculating the difference between the amount of high-fat food offered (previously measured) and the amount of uneaten food, within a 24 h interval. Energy intake and feeding efficiency were estimated using the following formulas [24] The adiposity index was determined by the sum of fat pads (subcutaneous, periuterine and retroperitoneal), divided by body mass × 100, and expressed as adiposity percentage [25] . Naso-anal and tibia length and uterus weight were also determined.
Intraperitoneal insulin and glucose tolerance tests
After 6 h of fasting, rats underwent an insulin tolerance test (ITT) and a glucose tolerance test (GTT). For the ITT, rats were subjected to an insulin injection (0.75 IU·kg −1 , i.p.). Blood glucose levels were determined in blood samples collected at basal (0), 5, 10, 15, 20, 25 and 30 min after the insulin injection. The glucose disappearance rate (Kitt) was calculated from the slope of the linear regression of blood glucose concentration from 5 to 30 min after insulin administration [26] . For the GTT, all rats received glucose (2.0 g·kg −1 , i.p., from a 20% solution of D-glucose) and blood glucose was measured in blood samples collected at 0, 15, 30, 60, 90 and 120 min after the infusion. The values were presented as the area under glucose curve (AUC). Blood samples were obtained from the tip of the tail for blood glucose determination using an Optium Xceed glucose meter (Abbott, Alameda, CA, USA).
Blood metabolite and hormone determinations
Trunk blood samples were collected after decapitation. Serum was separated by centrifugation at 239 ×g for 20 min at 4°C. Serum DHEA (Immunotech, Praha, Czech Republic, DSL-8900) and serum insulin levels (insulin labeled with 125 I, PerkinElmer, Boston, MA, USA) were measured using a radioimmunoassay. Estradiol (E 2 ) levels were quantified using an Elisa kit (IBL Hamburg, Germany, RE52041). Total cholesterol (TC), high-density lipoprotein (HDL), cholesterol, triacylglycerol (TAG), total protein, and albumin were determined with kits from Wiener (Rosario, Argentina). The activities of aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and the levels of urea and creatinine were measured using kits purchased from Labtest Diagnóstica (Minas Gerais, Brazil). For all measurements, the kits were employed using the recommendations of the manufacturers. Estimation of the low density lipoprotein (LDL) and very low density lipoprotein (VLDL) cholesterol levels was performed as previously described by Friedewald et al. [27] .
Immunoblotting
After loss of pedal and corneal reflexes by anesthesia, the abdominal cavity was opened and 200 μL normal saline (0.9% NaCl) or 20 IU insulin was injected into the portal vein. The gastrocnemius muscle was removed and immediately homogenized in 1.5 mL of boiling extraction buffer [100 mM Tris (pH 7.4), 100 mM sodium pyrophosphate, 100 mM sodium fluoride, 10 mM EDTA, 10 mM sodium vanadate and 10% SDS] using a Polytron-Aggregate (Luzern, Switzerland), after 30 and 90 s following the injection, respectively, as previously described [18] . The insoluble material was removed by centrifugation at 15,294 ×g for 40 min at 4°C. Protein quantification of the supernatant was assessed using the Bradford method [28] , and then treated with Laemmli buffer [29] plus 200 mM DTT. Fifty micrograms of protein were electrophoretically separated using 6.5% or 12% SDS-PAGE gels and transferred to nitrocellulose membranes (120 V for 2 h), in a miniature transfer apparatus (Bio-Rad, Hercules, CA, USA). Before incubation with the primary antibody, the membranes were treated with blocking buffer (5% nonfat dry milk, 10 mM Tris, 150 mM NaCl, and 0.02% Tween 20) for 2 h at room temperature to reduce non-specific protein binding. The membranes were incubated overnight at 4°C with primary antibody diluted in blocking buffer with 3% bovine serum albumin (BSA). Anti-phosphotyrosine (SC-508), anti-IRS2 (SC-8299) and antiAkt (SC-8312) antibodies were obtained from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-IRS1 (no. 06-248) and anti-phospho-IRS1 (Ser 307 ) (no. 07-247) antibodies were purchased from Millipore (Billerica, MA, USA). Anti-IRβ (no. 3025) antibody was purchased from Cell Signaling (Danvers, MA, USA). Anti-phospho-Akt (Ser 473 ) (no.
AF887) and anti-PI3-kinase p85α (no. 2998) antibodies were obtained from R&D Systems (Minneapolis, MN, USA). The blots were washed with blocking buffer without milk and subsequently incubated with peroxidase-conjugated secondary antibodies (Bio-Rad) for 1 h at room temperature. Thereafter, the immune complexes were detected using an Enhanced Chemiluminescence (ECL) kit (GE Healthcare, Buckinghamshire, UK) and visualized on a MF-Chemibis-Bio-Imaging System (DNR Bio-Imaging Systems, Jerusalem, Israel). Band intensities were quantified by optical densitometry using the ImageJ 1.46v software (NIH, USA). The results were normalized for total protein loading as indicated by Ponceau S staining [30] .
Statistical analysis
The results were expressed as means ± SD. Statistical analysis was performed using a two-way ANOVA followed by the Tukey post-hoc test (GraphPad Prism, Version 6.01, San Diego, CA, USA). Differences were considered significant for P < 0.05.
Results
Effects of DHEA on zoometric parameters and food intake
The efficacy of the ovariectomy was evidenced by an 80% reduction in uterus weight, as compared to SHAM rats (P < 0.05) ( Table 1) . OVX rats had elevated body weight gain, adiposity index, feeding efficiency and naso-anal length (by 22%, 65%, 59% and 6%, respectively) as compared to SHAM rats (P < 0.05) ( Table 1) . Administration of DHEA did not change these parameters (P > 0.05). In addition, no statistical differences were observed regarding food and energy intake in OVX rats as compared with SHAM rats (P > 0.05). Meanwhile, SHAM+DHEA and OVX + DHEA rats had an approximately 20% increase in food and energy intake as compared to vehicle-treated rats (P < 0.05), while DHEA treatment had no impact on feeding efficiency (P > 0.05) ( Table 1) . Furthermore, the tibia length was enhanced by 8% in OVX + DHEA rats when compared to SHAM rats (P < 0.05) ( Table 1) .
Administration of DHEA impaired whole-body insulin sensitivity
Neither basal insulin nor plasma glucose levels were affected by either ovariectomy or DHEA treatment (P > 0.05) ( Table 2 ). On the other hand, OVX and OVX + DHEA rats were glucose intolerant, as indicated by the increased AUC, as compared to SHAM rats (P < 0.05) (Fig. 1A, B) . The calculated Kitt was reduced by 22% in OVX rats as compared to SHAM rats (P < 0.05). DHEA treatment impaired wholebody insulin sensitivity by 20% in OVX rats (OVX + DHEA) when compared to vehicle-treated OVX rats (P < 0.05) (Fig. 1C, D) .
Effects of DHEA on blood hormone and metabolite levels
As expected, estradiol and DHEA levels were reduced by 65% and 48%, respectively, in OVX rats as compared to SHAM (P < 0.05) ( Table 2 ). The levels of these hormones in OVX + DHEA rats were restored to the values found in SHAM rats (P < 0.05) ( Table 2) . Plasma DHEA levels in SHAM+DHEA rats were 56% higher than in vehicletreated SHAM rats (P < 0.05) ( Table 2) .
Neither ALT nor AST levels were affected by either ovariectomy or DHEA treatment (P > 0.05) ( Table 2 ). On the other hand, OVX rats also displayed a decrease in plasma levels of VLDL-c (36%), triacylgycerol (40%), total protein (16%), albumin (22%), urea (23%) and creatinine (27%) as compared with SHAM rats (P < 0.05) ( Table 2) , and DHEA treatment had no effect on these parameters (P > 0.05).
Expression and phosphorylation status of proteins involved in the early steps of the insulin signaling pathway in the skeletal muscle
Skeletal muscle IRβ, IRS1, IRS2, PI3K and Akt protein expression, as well as the insulin-induced IRβ tyrosine phosphorylation was not different among groups (P > 0.05) ( Fig. 2A-G) . On the other hand, the insulin-induced IRS1/2 tyrosine phosphorylation was significantly reduced to 40% in the skeletal muscle of OVX rats, as compared to SHAM rats (P < 0.05) ( Fig. 2A and H) . However, there was no impact on serine phosphorylation in Akt or IRS1 (P > 0.05) (Fig. 2A, I and J). DHEA had no effect on protein expression or phosphorylation in the SHAM+DHEA or OVX + DHEA groups (P > 0.05).
Discussion
Premature or physiological aging of the ovaries represents one of the most common challenges for women [31, 32] . The influence of estrogen deficiency on metabolic disorders such as increasing abdominal fat gain, obesity, insulin resistance and glucose intolerance has been reported [1] [2] [3] [4] . In this regard, the precursor, DHEA, for extragonadal steroid synthesis in older females has emerged as a potential therapy for multiple disorders [33] . However, it should be mentioned that, side effects of DHEA supplementation have not been reported. The purpose of the current study was to determine if DHEA supplementation has an influence on the progression of glucose tolerance and insulin sensitivity observed in ovariectomized rats.
After menopause, the main source of estrogens comes from extragonadal sites, through the bioconversion of the androgens, testosterone The results were normalized for total protein loading as calculated using Ponceau S staining. Two-way ANOVA and Tukey's test were used for statistical analysis. Distinct letters over the bars indicate statistical significance for P < 0.05. and androstenedione, in the adipose tissue, skin, bone and vaginal epithelium, by the aromatase enzyme [34, 35] . Despite the fact that DHEA treatment restored plasma levels of DHEA and estrogen in OVX rats, the atrophy of the uterus did not change, which is a finding that is in accordance with our previous studies [21, 22] . In contrast to estrogen replacement, the DHEA transformation is cell-and tissue-specific, ranging from no estrogen bioconversion in the endometrium to a high bioconversion in the vaginal epithelium [34] . The tissue-specific absence of aromatase explains the increased systemic estradiol levels without uterus action [36, 37] . Furthermore, the cytokine effects on aromatase gene expression in adipose tissue [38] may play a role in the higher estrogen levels detected in the obese rats fed a high-fat diet and treated with DHEA. In this respect, Wang et al. [39] reported that a 3 month treatment with physiological DHEA levels increased the aromatase activity in the tibia, whereas estrogen treatment increased the aromatase activities in the uterus and tibia, of postmenopausal women. Therefore, it is plausible that local aromatase activity may explain the increased tibia length in the OVX + DHEA animals. Estrogen deficiency has been associated with increased body weight gain and intra-abdominal fat content, including visceral adipose tissue accumulation and the development and progression of non-alcoholic steatosis in both postmenopausal women [3] [4] [5] and OVX rodents [1, [40] [41] [42] . We found that OVX rats displayed an increased feeding efficiency that was reflected in an increased body mass and adiposity index. While previous reports have shown that DHEA supplementation reduced adiposity and improved insulin sensitivity in both humans [12, 13] and rodents [11, [14] [15] [16] , we did not observe any reduction in the body weight or adiposity. It was previously demonstrated that ovariectomy, as well as a high-fat diet, induce changes in estrogen receptor alpha (ERα) expression in the adipose tissue, which is the main mediator of estradiol effects on energy homeostasis [43] . Thus, it is possible that the OVX + DHEA group did not display a decreased adiposity index due to the loss of estrogen signaling caused by a reduction in ERα expression, which could directly impact adipose tissue metabolism [44] . In fact, we found impaired insulin sensitivity in the OVX + DHEA group when compared to the OVX group. Therefore, these findings do not corroborate with our previous studies [22] which reported the DHEA improved adiposity as well as insulin sensitivity in OVX rats fed a high-fat diet that induced obesity during early postmenopause (Fig. 3) .
This apparent contradiction could be explained by the "opportunitywindow" or "timing hypothesis", which describes how hormone therapy can be dependent on dose (e.g. low versus higher), duration (acute, chronic), postmenopausal period (early or late) and routes of administration (e.g. oral, transdermal) [6, 45, 46] . Villareal and Holloszy [12] reported improved insulin action after 6 months of oral DHEA (50 mg/d) administration in men and women (65-78 yr) with age-related decreases in DHEA levels. Weiss et al. [13] also reported a reduction in insulin resistance as well as an improvement in glucose tolerance in elderly, overweight or obese women and men, after 12 or 24 months of DHEA (50 mg/d) or placebo. However, Nair et al. [47] did not find any change in body composition, fasting insulin levels or insulin sensitivity in elderly men and women after 2 years of DHEA treatment (75 and 50 mg/d). Basu et al. [48] warned against the recommendation of DHEA as an anti-aging drug in elderly subjects, since there was no observed effect on insulin action or postprandial glucose levels after 2 years of DHEA treatment in elderly men and women. All of these results strongly argue against a role of DHEA deficiency in the pathogenesis of age-related deterioration in glucose tolerance.
The OVX group had lower serum VLDL-c and TAG levels compared with SHAM rats. This is probably due to the high rate of lipolysis coupled with the increased plasma free fatty acids levels that can be stored as TAG in the liver and exported as VLDL [49] . The increased fatty acid delivery to the liver might have led to increased TAG synthesis, reduced fatty acid oxidation, and fatty acid exportation in the VLDL form [50] . Along these lines, Barsalani et al. [51] found decreased VLDL-TAG synthesis and/or secretion in OVX Sprague-Dawley rats. They suggested that it was probably through the regulation of the microsomal TAG transfer protein (MTP) and might constitute one of the factors involved in hepatic fat accumulation. Four week treatment with a selective estrogen receptor modulator [52] reduced fasting and postprandial plasma TAG, an effect associated with a lower VLDL-TAG secretion rate and reduced MTP gene expression. MTP is an important protein for VLDL-c assembly and secretion of triglyceride-rich apoB-containing VLDL lipoprotein [41, 51] . Although DHEA is believed to protect females against chronic disorders, less is known about the impact of DHEA administration on the lipoprotein profile in women. Herein, the DHEA treatment did not change the levels of VLDL or TAG in the OVX + DHEA group. However, Srinivasan et al. [53] reported detrimental effects such as reductions in total plasma cholesterol despite observing reductions in large and small HDL particles after the administration of 50 mg/d oral DHEA for 3 months.
Despite not presenting data on cytokines we suggest that the reduced plasma albumin levels observed in the OVX and OVX + DHEA groups can be due to increased pro-inflammatory cytokines usually observed in obesity [54] . Inflammatory disorders have been reported to decrease serum albumin by several mechanisms, including down regulated synthesis and increased catabolism, as well as low total protein [55] . Therefore, pro-inflammatory cytokines might activate serine kinases and negatively regulate the insulin signaling through serine phosphorylation sites in the IRS proteins [56] . In fact, it has been observed that ovariectomy can impair the insulin signaling pathway in the liver [57] and skeletal muscle [57] [58] [59] . We also have shown that IRS1/2 tyrosine phosphorylation was decreased in the skeletal muscle of OVX rats and that DHEA treatment did not alter it, despite previous reports showed that DHEA increased the insulin-induced tyrosine phosphorylation of IRS1, but not IRS2, in the skeletal muscle from male rodents [18, 23] .
In summary, the prolonged DHEA treatment did not change the adiposity index, impaired insulin sensitivity or the PI3K/Akt signaling pathway in the skeletal muscle of OVX rats. Therefore, similar to estrogen therapy in women, the use of DHEA seems to be inefficient in the late postmenopausal period at least in diet-induced obese OVX rats.
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